Literature DB >> 9566469

Power and sample size calculations for stochastic cost-effectiveness analysis.

A H Briggs1, A M Gray.   

Abstract

As the data for economic analyses are increasingly collected prospectively alongside clinical trials, many commentators have highlighted that the sample sizes in such trials should be based on the requirements for the economic analysis as well as those for the clinical evaluation. However, issues associated with sample size calculations for economic analysis have yet to receive the rigorous attention given to sample size calculation for clinical evaluation. In particular, no sample size formula for cost-effectiveness analysis is available for analysts hoping either to calculate the required sample size at the design stage of a study or to calculate the power a given size of clinical trial will generate for cost-effectiveness analysis. Building on the recent literature for calculating confidence intervals for cost-effectiveness ratios, the authors explore possible techniques for deriving a sample size formula for cost-effectiveness analysis based on simple combination of the confidence limits on costs and effects.

Mesh:

Year:  1998        PMID: 9566469     DOI: 10.1177/0272989X98018002S10

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  20 in total

1.  Economic evaluation and clinical trials: size matters.

Authors:  A Briggs
Journal:  BMJ       Date:  2000-12-02

2.  Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.

Authors:  Martin E Backhouse
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Authors:  Niklas Zethraeus; Magnus Johannesson; Bengt Jönsson; Mickael Löthgren; Magnus Tambour
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 4.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

5.  Guidelines for conducting and reporting economic evaluation of fall prevention strategies.

Authors:  J C Davis; M C Robertson; T Comans; P A Scuffham
Journal:  Osteoporos Int       Date:  2010-11-23       Impact factor: 4.507

Review 6.  Estimation, power and sample size calculations for stochastic cost and effectiveness analysis.

Authors:  S D Walter; Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

7.  Sample size and power for cost-effectiveness analysis (part 1).

Authors:  Henry A Glick
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

8.  A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke.

Authors:  Denise M Boudreau; Greg Guzauskas; Kathleen F Villa; Susan C Fagan; David L Veenstra
Journal:  Ann Emerg Med       Date:  2012-05-24       Impact factor: 5.721

9.  Evaluating the Financial Sustainability of the School-Based Telemedicine Asthma Management Program.

Authors:  Christina Crabtree-Ide; Denise F Lillvis; Jing Nie; Maria Fagnano; Reynaldo S Tajon; Paul Tremblay; Jill S Halterman; Katia Noyes
Journal:  Popul Health Manag       Date:  2021-05-14       Impact factor: 2.459

10.  Predicting sample size required for classification performance.

Authors:  Rosa L Figueroa; Qing Zeng-Treitler; Sasikiran Kandula; Long H Ngo
Journal:  BMC Med Inform Decis Mak       Date:  2012-02-15       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.